MDC Max Delbrück Center for Molecular Medicine in the Helmholtz Association
The MDC Max Delbrück Center for Molecular Medicine in the Helmholtz Association ranks among the top institutions in the world for basic biomedical research. MDC scientists use state-of-the-art methods of molecular biology and genetic engineering in order to understand the development of complex diseases at their origin, in the genes. On this basis, they seek to develop new methods to diagnose, treat and prevent diseases. Research activities at the MDC are divided into four main areas: cardiovascular and metabolic diseases, cancer, diseases of the nervous system and medical systems biology. MDC researchers collaborate closely with the Charité in the Experimental and Clinical Research Center and also with biotech companies located on Campus Berlin-Buch. The MDC currently employs approximately 1,700 staff members, including guest scientists, and has state-of-the-art technology platforms such as 7 Tesla ultra high field MRI, electron microscopy or bioinformatics.
Leibniz Research Institute for Molecular Pharmacology (FMP)
How do diseases develop? Which drugs can specifically target and intervene in the biochemistry of the body? Research activities at the Leibniz Research Institute for Molecular Pharmacology (FMP), Germany’s only non-university research institute for pharmacology, are concerned with these questions. Chemists, biologists, pharmacologists, physicists and physicians collaborate closely to lay the basis for the development of future drugs.
The FMP cooperates with other Berlin research institutions such as the Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin and is part of several research projects, such as the Neurocure cluster of excellence. The institute is also one of the initiators of the large-scale European project EU-OPENSCREEN, in which institutions from various European countries want to coordinate the search for new drugs, and part of the new European network “Instruct”, which seeks to link the highly sophisticated technologies in structural biology.
The institute has a staff of 300 employees and is a member of the Leibniz Association and the Forschungsverbund Berlin e.V. (Berlin Research Association).
Where science turns into business
On April 25, 2022, Federal Commissioner for East Germany, Minister of State Carsten Schneider, and Governing Mayor of Berlin Franziska Giffey visited Campus Berlin-Buch to see how the “Zukunftsort” (p...more ...
COVID-19 therapy: better in combination than alone
More and more drugs are available for the treatment of COVID-19. Researchers from Charité, FU and MDC in Berlin have investigated the mechanisms of action of antiviral and anti-inflammatory substances...more ...
High-ranking naked mole-rats are more resilient
Naked mole-rats are full of surprises. The latest is that higher-ranked mole-rats most likely have an immunological advantage over animals with lower social status, a discovery made by Professor Gary ...more ...
Buchpräsentation: Cécile Vogt – Pionierin der Hirnforschung!
Die Autorin Birgit Kofler-Bettschart stellt ihre Biografie über die Wegbereiterin der modernen Hirnforschung vormore ...
CampusVital LOUNGE: Was der Darm über das Herz verrät
Alle Interessierten sind herzlich zur CampusVital LOUNGE im Café rock-raper (Mensafoyer) eingeladenmore ...
Lange Nacht der Wissenschaften auf dem Campus Berlin-Buch und am MDC in Mitte
Wer das Leben verstehen will, sollte sich auch auf die Welt der Moleküle einlassen. Dass das nicht nur für Experten interessant ist, zeigt das Programm des Campus Berlin-Buch/MDC-Mitte während der Lan...more ...